Henk M De Feyter1, Raimund I Herzog2, Bart R Steensma3, Dennis W J Klomp3, Peter B Brown1, Graeme F Mason1, Douglas L Rothman1,4, Robin A de Graaf1,4. 1. Department of Radiology and Biomedical Imaging, Magnetic Resonance Research Center, Yale University School of Medicine, New Haven, Connecticut, USA. 2. Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA. 3. Department of Radiology, University Medical Center Utrecht, Utrecht, Netherlands. 4. Department of Biomedical Engineering, Magnetic Resonance Research Center, Yale University School of Medicine, New Haven, Connecticut, USA.
Abstract
PURPOSE: 13 C magnetic resonance spectroscopy (MRS) in combination with infusion of 13 C-labeled substrates has led to unique insights into human brain metabolism and neurotransmitter cycling. However, the low sensitivity of direct 13 C MRS and high radiofrequency power requirements has limited 13 C MRS studies to predominantly data acquisition in large volumes of the occipital cortex. The purpose of this study is to develop an MRS technique for localized detection of 13 C-labeling of glutamate and glutamine in the human frontal lobe. METHODS: We used an indirect (1 H-[13 C]), proton-observed, carbon-edited MRS sequence (selPOCE) for detection of 13 C-labeled metabolites in relatively small volumes located in the frontal lobe at 4 T. The SelPOCE method allows for selective and separate detection of glutamate and glutamine resonances, which significantly overlap at magnetic field strengths used for clinical MRI. RESULTS: Phantom data illustrate how selPOCE can be tuned to selectively detect 13 C labeling in different metabolites. Three-dimensional specific absorption rate simulations of radiofrequency power deposition show that the selPOCE method operates comfortably within the global and local Food and Drug Administration specific absorption rate guidelines. In vivo selPOCE data are presented, which were acquired from a 45-mL volume in the frontal lobe of healthy subjects. The in vivo data show the time-dependent 13 C-labeling of glutamate and glutamine during intravenous infusion of [1-13 C]-glucose. Metrics describing spectral fitting quality of the glutamate and glutamine resonances are reported. CONCLUSIONS: The SelPOCE sequence allows the detection of 13 C-labeling in glutamate and glutamine from a relatively small volume in the human frontal lobe at low radiofrequency power requirements. Magn Reson Med 80:11-20, 2018.
PURPOSE:13 C magnetic resonance spectroscopy (MRS) in combination with infusion of 13 C-labeled substrates has led to unique insights into human brain metabolism and neurotransmitter cycling. However, the low sensitivity of direct 13 CMRS and high radiofrequency power requirements has limited 13 CMRS studies to predominantly data acquisition in large volumes of the occipital cortex. The purpose of this study is to develop an MRS technique for localized detection of 13 C-labeling of glutamate and glutamine in the human frontal lobe. METHODS: We used an indirect (1 H-[13 C]), proton-observed, carbon-edited MRS sequence (selPOCE) for detection of 13 C-labeled metabolites in relatively small volumes located in the frontal lobe at 4 T. The SelPOCE method allows for selective and separate detection of glutamate and glutamine resonances, which significantly overlap at magnetic field strengths used for clinical MRI. RESULTS: Phantom data illustrate how selPOCE can be tuned to selectively detect 13 C labeling in different metabolites. Three-dimensional specific absorption rate simulations of radiofrequency power deposition show that the selPOCE method operates comfortably within the global and local Food and Drug Administration specific absorption rate guidelines. In vivo selPOCE data are presented, which were acquired from a 45-mL volume in the frontal lobe of healthy subjects. The in vivo data show the time-dependent 13 C-labeling of glutamate and glutamine during intravenous infusion of [1-13 C]-glucose. Metrics describing spectral fitting quality of the glutamate and glutamine resonances are reported. CONCLUSIONS: The SelPOCE sequence allows the detection of 13 C-labeling in glutamate and glutamine from a relatively small volume in the human frontal lobe at low radiofrequency power requirements. Magn Reson Med 80:11-20, 2018.
Authors: J W Pan; D T Stein; F Telang; J H Lee; J Shen; P Brown; G Cline; G F Mason; G I Shulman; D L Rothman; H P Hetherington Journal: Magn Reson Med Date: 2000-11 Impact factor: 4.668
Authors: R A de Graaf; J W Pan; F Telang; J H Lee; P Brown; E J Novotny; H P Hetherington; D L Rothman Journal: J Cereb Blood Flow Metab Date: 2001-05 Impact factor: 6.200
Authors: Li An; Shizhe Li; James B Murdoch; Maria Ferraris Araneta; Christopher Johnson; Jun Shen Journal: Magn Reson Med Date: 2014-02-28 Impact factor: 4.668
Authors: D L Rothman; E J Novotny; G I Shulman; A M Howseman; O A Petroff; G Mason; T Nixon; C C Hanstock; J W Prichard; R G Shulman Journal: Proc Natl Acad Sci U S A Date: 1992-10-15 Impact factor: 11.205
Authors: Chadi G Abdallah; Henk M De Feyter; Lynnette A Averill; Lihong Jiang; Christopher L Averill; Golam M I Chowdhury; Prerana Purohit; Robin A de Graaf; Irina Esterlis; Christoph Juchem; Brian P Pittman; John H Krystal; Douglas L Rothman; Gerard Sanacora; Graeme F Mason Journal: Neuropsychopharmacology Date: 2018-06-28 Impact factor: 7.853
Authors: Henk M De Feyter; Kevin L Behar; Zachary A Corbin; Robert K Fulbright; Peter B Brown; Scott McIntyre; Terence W Nixon; Douglas L Rothman; Robin A de Graaf Journal: Sci Adv Date: 2018-08-22 Impact factor: 14.136
Authors: James T Grist; Jack J Miller; Fulvio Zaccagna; Mary A McLean; Frank Riemer; Tomasz Matys; Damian J Tyler; Christoffer Laustsen; Alasdair J Coles; Ferdia A Gallagher Journal: J Cereb Blood Flow Metab Date: 2020-03-10 Impact factor: 6.200